Clinical Trials in Seoul, Korea
1 recruiting
Showing 1–6 of 6 trials
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled193 locationsNCT05827081
Recruiting
Phase 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled5 locationsNCT07006727
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled30 locationsNCT06726148
Recruiting
Phase 1Phase 2
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company540 enrolled49 locationsNCT04956640
Recruiting
Phase 4
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Breast CancerNode-positive Breast CancerHER2-negative Breast Cancer+2 more
Gangnam Severance Hospital418 enrolled2 locationsNCT05333328
Recruiting
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals250 enrolled12 locationsNCT05703516